Johnson & Johnson has
begun clinical trials for an Ebola vaccine in Sierra Leone. The vaccine regimen is
part of a new study being conducted in Sierra Leone's Kambia district, where
some of the country's most recent Ebola cases have been reported.
Associated
Press report that the study, in development at subsidiary Janssen
Pharmaceutical Cos., will evaluate safety and immune response within Sierra
Leone's general population.
The
company said Friday that the first volunteers have received the initial dose.
Johnson
& Johnson, based in New Brunswick, New Jersey, said that there are separate
studies being conducted in the U.S., Europe and Africa as part of the
accelerated development plan to prevent Ebola outbreaks.
There is currently no
licensed vaccine, treatment or cure for the Ebola virus.
No comments:
Post a Comment